Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases

References

• Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86. doi:10.1016/j.hoc.2009.11.011
   PubMed Web of Science ®Google Scholar
• Gutierrez JC, Fischer AC, Sola JE, Perez EA, Koniaris LG. Markedly improving survival of neuroblastoma: a 30-year analysis of 1646 patients. Pediatr Surg Int. 2007;23(7):637–646. doi:10.1007/s00383-007-1933-7
   PubMed Web of Science ®Google Scholar
• Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–2211. doi:10.1056/NEJMra0804577
   PubMed Web of Science ®Google Scholar
• Basta NO, Halliday GC, Makin G, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115(9):1048–1057. doi:10.1038/bjc.2016.302
   PubMed Web of Science ®Google Scholar
• Dübbers M, Simon T, Berthold F, et al. Retrospective analysis of relapsed abdominal high-risk neuroblastoma. J Pediatr Surg. 2018;53:558–566. doi:10.1016/j.jpedsurg.2017.09.002
   PubMed Web of Science ®Google Scholar
• London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29(24):3286–3292. doi:10.1200/JCO.2010.34.3392
   PubMed Web of Science ®Google Scholar
• Murphy JM, Lim II, Farber BA, et al. Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass. J Pediatr Surg. 2016;51(2):285–288. doi:10.1016/j.jpedsurg.2015.10.075
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang J, Zhen ZJ, et al. Brain metastasis in children with stage 4 neuroblastoma after multidisciplinary treatment. Chin J Cancer. 2015;34:531–537. doi:10.1186/s40880-015-0038-2
   PubMedGoogle Scholar
• Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–1477. doi:10.1200/JCO.1993.11.8.1466
   PubMed Web of Science ®Google Scholar
• Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86:364–372. doi:10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• George RE, London WB, Cohn SL, et al. Hyperdiploidy plus NonamplifiedMYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a pediatric oncology group study. J Clin Oncol. 2005;23(27):6466–6473. doi:10.1200/JCO.2005.05.582
   PubMed Web of Science ®Google Scholar
• Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 Months of age with stage 4 nonamplified MYCN neuroblastoma: a children’s cancer group study. J Clin Oncol. 2005;23(27):6474–6480. doi:10.1200/JCO.2005.05.183
   PubMed Web of Science ®Google Scholar
• Ishiguro Y, Kato K, Ito T, Nagaya M, Yamada N, Sugito T. Nervous system-specific enolase in serum as a marker for neuroblastoma. Pediatrics. 1983;72(5):696–700. doi:10.1542/peds.72.5.696
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Marangos PJ, Parma AM, et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children’s Cancer Study Group. Lancet. 1983;2(8346):361–363. doi:10.1016/S0140-6736(83)90342-2
   PubMed Web of Science ®Google Scholar
• Ferraro S, Braga F, Luksch R, Terenziani M, Caruso S, Panteghini M. Measurement of serum neuron-specific enolase in neuroblastoma: is there a clinical role? Clin Chem. 2020;66(5):667–675. doi:10.1093/clinchem/hvaa073
   PubMed Web of Science ®Google Scholar
• Moroz V, Machin D, Hero B, et al. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020;67(8):e28359. doi:10.1002/pbc.28359
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106–2120. doi:10.1016/S0140-6736(07)60983-0
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214. doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD; INRG Task Force, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–297. doi:10.1200/JCO.2008.16.6785.
   PubMed Web of Science ®Google Scholar
• Park JR, Bagatell R; COG Neuroblastoma Committee, et al. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985–993. doi:10.1002/pbc.24433
   PubMed Web of Science ®Google Scholar
• London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005;23(27):6459–6465. doi:10.1200/JCO.2005.05.571
   PubMed Web of Science ®Google Scholar
• Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 1971;31(12):2098–2103.
   PubMed Web of Science ®Google Scholar
• Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73(2):405–416. doi:10.1093/jnci/73.2.405
   PubMedGoogle Scholar
• Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–1124. doi:10.1126/science.6719137
   PubMed Web of Science ®Google Scholar
• Otte J, Dyberg C, Pepich A, Johnsen JI. MYCN function in neuroblastoma development. Front Oncol. 2021;10:624079. doi:10.3389/fonc.2020.624079
   PubMed Web of Science ®Google Scholar
• Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A. 1984;81:4940–4944. doi:10.1073/pnas.81.15.4940
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 2003;39(13):1899–1903. doi:10.1016/S0959-8049(03)00376-9
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961–970. doi:10.3109/0284186X.2015.1043026
   PubMed Web of Science ®Google Scholar
• Zhang J, Yao YH, Li BG, Yang Q, Zhang PY, Wang HT. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep. 2015;5:9800. doi:10.1038/srep09800
   PubMed Web of Science ®Google Scholar
• Konjević G, Jurisić V, Jakovljević B, Spuzić I. Lactate dehydrogenase (LDH) in peripheral blood lymphocytes (PBL) of patients with solid tumors. Glas Srp Akad Nauka Med. 2002;47:137–147.
   Google Scholar
• Mossé YP, Deyell RJ, Berthold F, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61:627–635. doi:10.1002/pbc.24777
   PubMed Web of Science ®Google Scholar
• DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21:181–189. doi:10.1097/00043426-199905000-00005
   PubMed Web of Science ®Google Scholar
• Berthold F, Boos J, Burdach S, Hero B. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649–658. doi:10.1016/S1470-2045(05)70291-6
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998;16(3):953–965. doi:10.1200/JCO.1998.16.3.953
   PubMed Web of Science ®Google Scholar
• Saarinen-Pihkala UM, Hovi L, Koivusalo A, et al. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma. Pediatr Blood Cancer. 2012;59:1190–1197. doi:10.1002/pbc.24173
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Kodama Y, Nishikawa T, Kawano Y. Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma. Pediatr Hematol Oncol. 2017;34:157–164. doi:10.1080/08880018.2017.1348414
   PubMed Web of Science ®Google Scholar
• Kushner BH, Ostrovnaya I, Cheung IY, Cheung NK. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7:4155–4166. doi:10.18632/oncotarget.6393
   PubMed Web of Science ®Google Scholar